Abstract
Lung cancer is the leading cause of cancer related deaths accounting for more deaths than breast, colon and prostate cancers combined. The Rb-p16 regulatory pathway plays an essential role in tumor suppression in the lung epithelium. This is evidenced by the nearly universal alterations in Rbp16 pathway components in lung cancer, and the increased incidence of pulmonary carcinomas in persons with germline Rb mutations. Interestingly, p16 loss and Rb mutations preferentially occur in phenotypically distinct lung cancer subtypes. Analysis of human tumors has identified progressive preneoplastic lesions that accumulate molecular alterations in an orderly sequence. Epigenetic p16 gene modifications represent an early event in lung cancer progression. This review summarizes the human studies that demonstrate a critical role for the Rb-p16 tumor suppressor pathway in lung carcinogenesis, and discusses how these findings in combination with genetically engineered mouse models have significantly contributed to our understanding of lung cancer pathogenesis.
Keywords: Lung cancer, retinoblastoma, Rb, p16, cyclin D, p130
Current Molecular Medicine
Title: Retinoblastoma Regulatory Pathway in Lung Cancer
Volume: 6 Issue: 7
Author(s): Kathryn A. Wikenheiser-Brokamp
Affiliation:
Keywords: Lung cancer, retinoblastoma, Rb, p16, cyclin D, p130
Abstract: Lung cancer is the leading cause of cancer related deaths accounting for more deaths than breast, colon and prostate cancers combined. The Rb-p16 regulatory pathway plays an essential role in tumor suppression in the lung epithelium. This is evidenced by the nearly universal alterations in Rbp16 pathway components in lung cancer, and the increased incidence of pulmonary carcinomas in persons with germline Rb mutations. Interestingly, p16 loss and Rb mutations preferentially occur in phenotypically distinct lung cancer subtypes. Analysis of human tumors has identified progressive preneoplastic lesions that accumulate molecular alterations in an orderly sequence. Epigenetic p16 gene modifications represent an early event in lung cancer progression. This review summarizes the human studies that demonstrate a critical role for the Rb-p16 tumor suppressor pathway in lung carcinogenesis, and discusses how these findings in combination with genetically engineered mouse models have significantly contributed to our understanding of lung cancer pathogenesis.
Export Options
About this article
Cite this article as:
Wikenheiser-Brokamp A. Kathryn, Retinoblastoma Regulatory Pathway in Lung Cancer, Current Molecular Medicine 2006; 6 (7) . https://dx.doi.org/10.2174/1566524010606070783
DOI https://dx.doi.org/10.2174/1566524010606070783 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Integrated, Molecular Engineering Approaches to Develop Prostate Cancer Gene Therapy
Current Gene Therapy Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry The Interest of Folic Acid in Targeted Photodynamic Therapy
Current Medicinal Chemistry ING Proteins as Potential Anticancer Drug Targets
Current Drug Targets Myocardial Regeneration: What is the Best Approach?
Current Cardiology Reviews The Neuroendocrine Component in Bladder Tumors
Current Medicinal Chemistry IP6 in Cancer Therapy: Past, Present and Future
Current Cancer Therapy Reviews Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Cell Cycle Arrest as a Therapeutic Target of Acute Kidney Injury
Current Protein & Peptide Science Local Gene Delivery for Cancer Therapy
Current Gene Therapy Regulatory Circuitries Coordinated by Transcription Factors and microRNAs at the Cornerstone of Hematopoietic Stem Cell Self-Renewal and Differentiation
Current Stem Cell Research & Therapy Development of Genetic Testing for Breast, Ovarian and Colorectal Cancer Predisposition: A Step Closer to Targeted Cancer Prevention
Current Drug Targets Possible Physiopathological Effects of the Transglutaminase Activity on the Molecular Mechanisms Responsible for Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Genomic Sequencing of Key Genes in Mouse Pancreatic Cancer Cells
Current Molecular Medicine Possible Role of DNA Methylation in the Induction of Systemic Lupus Erythematosus
Current Rheumatology Reviews Receptor Tyrosine Kinases as Target for Anti-Cancer Therapy
Current Pharmaceutical Design C/EBP Transcription Factors in Lung Disease
Current Respiratory Medicine Reviews Wide-Ranging Genomic Effects of Plasticisers and Related Compounds
Current Drug Metabolism Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets